Lepu Medical Acquires Majority Stakes in Shenda Endoscope

Lepu Medical acquires 60% stake in Shenda Endoscope through its Series C financing and becomes the controlling shareholder of Shenda Endoscope.
Established in the 1980s, China Shenyang-based Shenda Endoscope Co., Ltd. is an enterprise that develops, produces and sells medical rigid endoscopes, minimally invasive surgical instruments and medical electrical products. The founder of the company, professor-level senior engineer Kerang Jiang, successfully developed the first curved hysteroscope in China in 1975, which laid the foundation for the company’s product development direction.
In January 2021 Shenda Endoscope closed 130 million yuan of Series B financing co-led by Jinding Capital and Shanghai SciNova Investment, and followed by HIIG Investment, to develop new products, construct sales channels, as well as accelerate the IPO process.
Shenda Endoscope has launched more than 60 categories of products that can be applied to eight fields of minimally invasive surgery, including urology, gynaecology, orthopaedics, pentacameral surgery, general surgery, neurosurgery, gastroenterology and electronic endoscopy. Shenda Endoscope has nearly 400 customers of tier 3A hospitals in China including many leading hospitals such as Peking Union Medical College Hospital (PUMCH). Its products are used by more than 2,000 medical institutions in 70 countries.
Lepu Medical’s business covers three segments: medical devices, pharmaceuticals, medical services and health management. Covering cardiovascular implant interventions, in vitro diagnostics, and surgical anaesthesia, Lepu Medical’s medical device business is the largest revenue segment which contributed operating revenue of 5,879 million yuan in 2022, a year-on-year increase of 35.64%.
In 2021 Lepu Medical acquired Beijing-based Huake Chuangzhi Company which received approval from China’s National Medical Products Administration (NMPA) for Vsonic 600 ultrasound diagnostic equipment for digestive tract endoscopy in June 2022.
The Post is Available in: English – 简体中文
